HOME >> MEDICINE >> NEWS
Major ovarian cancer clinical study announced at Yale using combination drug therapy

A clinical study of ovarian cancer initiated by investigators at Yale School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women with recurrent ovarian cancer.

"Advanced-stage ovarian cancer is one of the most devastating forms of cancer, with half of the women diagnosed with it dying within five years," said principal investigator Thomas Rutherford, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale and a member of the Yale Cancer Center. "One of the imperatives facing doctors who treat these patients is to find ways to restore sensitivity to drugs such as taxanes once they start to lose that sensitivity."

The Phase Ib/IIa clinical study is supported by Sanofi-Aventis and Marshall Edwards, Inc. It will combine phenoxodiol, which is in the investigational phase with docetaxel, a second-generation taxane--drug that inhibits cell growth by stopping cell division--commonly used in patients with recurrent or persistent ovarian cancer that has failed other therapies, including the first generation taxane paclitaxel. The clinical response rate to any chemotherapeutic is often limited due to rapid development of chemo-resistance in women with recurrent ovarian cancer.

The purpose of the study is to determine if the addition of phenoxodiol to docetaxel can improve clinical response and survival by delaying or preventing the development of chemo-resistance in women with recurrent ovarian cancer.

The study will enroll 60 women with recurrent epithelial ovarian, fallopian tube or abdominal cavity cancer after treatment with a platinum and paclitaxel. All 60 patients will be given docetaxel by injection weekly; half the patients will also be given oral phenoxodiol daily, and the other half a placebo tablet. Tumor response will be determined on the basis of tumor burden (RECIST criteria) in patients with measurable disease, and tumor marker levels (GCIG criteria
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Nov-2005


Page: 1 2

Related medicine news :

1. Chinese space agency joins the International Charter Space and Major Disasters
2. Major employers, physicians, stakeholders unite to revolutionize Americas healthcare system
3. Majority of herb users dont follow evidence-based indications, researchers find
4. Majority of state Medicaid programs have or plan to have pay-for-performance programs
5. Major discovery raises prospect of better patient care by improving platelet life span
6. Major visual disorders in people over 40 may be costing the US economy billions
7. Major cancer study aims to identify protein markers for early-stage disease
8. Majority of health care opinion leaders say Medicare Part D helps beneficiaries, changes are needed
9. Major grant to IU School of Medicine will expand HIV/AIDS programs in Kenya
10. Major WHO study concludes calcium supplements can reduce complications during pregnancy
11. Major biomarker candidates for Alzheimers disease explored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... CHICAGO (PRWEB) , ... September 03, 2020 , ... ... Medical Spa Show 2021 will be held Wednesday, April 7, to Saturday, April ... late January. , Medical Spa Show is a national trade show for non-invasive ...
(Date:9/1/2020)... ... September 01, 2020 , ... KitoTech Medical, a ... note financing, which will be used to accelerate the commercialization of its microMend® ... the company will continue to expand its customer base of healthcare systems as ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced the 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its international ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University ... career-relevant, and affordable online education – is proud to announce its new master’s ... first of its kind in the nation, the 60-credit hour program is designed ...
(Date:8/31/2020)... ... 2020 , ... Dr. Chang has over 20 years of ... developmental disabilities, as well as supporting staff in caring for patients and families. ... and staff development. She joined the company in 2015 as Chief of Clinical ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... (PRWEB) , ... September 03, 2020 , ... Using Analysis ... FDAnews Webinar, Thursday, Sept. 17, 2020, 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/anova , ... expert statistician? , While one can’t become one in 90 minutes, one can ...
(Date:9/2/2020)... ... September 02, 2020 , ... ... , Advanced Penetration Technology, LLC, (APT) a Texas- and Indiana-based company ( ... Over The Counter (OTC) products, was today provided results of an independent ...
(Date:9/1/2020)... ... September 01, 2020 , ... ... Cosmetics and Laser Surgery at the University of Rochester Medical Center, in Upstate ... SkinCare Physicians in Boston, with clinical faculty from the Harvard and Yale Departments ...
Breaking Medicine Technology:
Cached News: